Olanzapine —continued weight gain with

An extension study for patients completing a 52-week core study with olanzapine or asenapine continued until study blind was broken [19 ]. Adverse event incidence was lower during the extension than during the core study and weight gain and incidence of extrapyramidal symptoms were negligible in both groups. 

---